Latest Share Chat

Venn Life Sciences Share News (VENN)

Venn Life Sciences Information

There is currently no data for VENN

Rightmove Chairman sells 7m pounds of shares

Tue, 27th May 2014 15:09

Rightmove's Chairman Scott Forbes has offloaded nearly a half of a holding in the property website group, selling over seven million pounds in shares.Forbes, who has been in his current role since 2005, sold 300,000 shares at an average price of 2,350.81p each, raising a total of £7.05m.Following the deal, his holding was reduced to 319,300 shares, representing a 0.3221% stake in the company.Rightmove said earlier this month that it had made a "positive start" to 2014 as audience continued to grow with page impressions up 14% in the first four months of the year.Meanwhile, the company generated a record 14.8m enquiries for its customers, up 30% on the year, while average revenues per advertiser showed "healthy growth".The business has been boosted over the past year by the recent boom in the UK housing market. However, competition has increased in recent months with rival firm Zoopla announcing its intention to float in June and another property portal called Agent Mutual due to launch next January.Rightmove's shares have fallen by around 15% in the year-to-date but have still risen by nearly 500% since the stock first listed in 2006.Top Director BuysEveryman Media Group (EMAN) Director name: Mr Adam KayeAmount purchased: 207,409 @ 89.00p Value: £184,594REA Holdings (RE.) Director name: Mr David BlackettAmount purchased: 10,000 @ 470.00p Value: £47,000Venn Life Sciences Holdings (VENN) Director name: Mr David Eric EvansAmount purchased: 210,000 @ 20.50p Value: £43,050Dunedin Enterprise Investment Trust (DNE) Director name: Mr Brian FinlaysonAmount purchased: 6,600 @ 429.78p Value: £28,365Wolf Minerals Limited (WLFE) Director name: Mr Russell Clark Amount purchased: 83,333 @ 30.00p Value: £25,000Kea Petroleum (KEA) Director name: Mr Ian Roderick Gowrie-SmithAmount purchased: 865,140 @ 1.95p Value: £16,870NWF Group (NWF) Director name: Mr Philip ActonAmount purchased: 10,000 @ 155.00p Value: £15,500Laird (LRD) Director name: Mr David LockwoodAmount purchased: 4,163 @ 283.59p Value: £11,806Top Director SellsRightmove (RMV) Director name: Mr Scott ForbesAmount sold: 300,000 @ 2,350.81p Value: £7,052,430Grafton Group Units (GFTU) Director name: Mr Gavin SlarkAmount sold: 41,700 @ 585.00p Value: £243,945Hansa Trust 'A' Non Voting Shares (HANA) Director name: Professor Geoffrey WoodAmount sold: 6,500 @ 960.00p Value: £62,400Hansa Trust (HAN) Director name: Professor Geoffrey WoodAmount sold: 5,000 @ 952.00p Value: £47,600Dunedin Enterprise Investment Trust (DNE) Director name: Mr Brian FinlaysonAmount sold: 5,975 @ 475.00p Value: £28,381BC

More News

27 May 2014 13:46

DIRECTOR DEALINGS: Venn Life Sciences Chairman Buys Shares

LONDON (Alliance News) - Venn Life Sciences Holdings PLC Tuesday said Chairman David Evans bought 210,000 shares at a price of 20.5 pence per share. Following this transaction, Evans now holds 289,033 shares. Shares in the clinical trial services company were trading flat at 20.5 penc

16 May 2014 12:56

Venn Life Sciences scores multi-million euro contract

AIM-listed clinical research organisation Venn Life Sciences announced it has scored a multi-million euro contract with a major European biotechnology company. The agreement, which is spread out over a year and a half and spans over seven European countries as well as a number of US sites, will see

16 May 2014 12:03

Venn Life Sciences 2013 Loss Widens On Lower Revenue

LONDON (Alliance News) - Venn Life Sciences Holdings PLC Friday posted a widened pretax loss in 2013, as it saw revenue decline, and announced a new contract win. The clinical research organisation posted a pretax loss of EUR1.8 million, widened from EUR1.2 million in the previous year, as

21 Mar 2014 13:43

Venn Life Sciences Finance Director Resigns

LONDON (Alliance News) - Venn Life Sciences Holdings PLC Friday said its Finance Director Paul Foulger has given notice of intention to resign from its board from April 14. The pharmaceutical and biotechnology company said Foulger now plans to pursue a full-time role within another public c

14 Mar 2014 08:23

UK MORNING BRIEFING: Shares Open Lower; BP Gets US Bid Approval

LONDON (Alliance News) - Shares have opened lower Friday on geopolitical worries ahead of the weekend, despite some good news for UK companies.

The US government on Thursday decided to lift the ban on BP from federal government contracts imposed after the Deepwater

14 Mar 2014 07:50

Venn Life Sciences Raises GBP1 Million In Placing

LONDON (Alliance News) - Venn Life Sciences Holdings PLC Friday said it has raised GBP1 million before expenses by placing 5.3 million shares at 19 pence each, funds it will use to develop the Labskin and potential acne treatment it recently acquired. The placing is conditional on sharehold

26 Feb 2014 10:04

Evocutis Slides As It Finally Sells Assets To Venn Life Sciences

LONDON (Alliance News) - Evocutis PLC saw its shares slide by a third Wednesday after it finally sold its assets after months of talks, leaving it as an investment shell. In a statement, Evocutis said it had sold all the intellectual property rights for its Labskin product and SYN1113 inves

31 Oct 2013 13:32

Venn Life Sciences To Acquire Trade, Business Assets Of CRM Clinical Trials GmbH For EUR0.6M

3 Oct 2013 12:11

DIRECTOR DEALINGS: Venn Life Sciences CEO Transfers Shares To Pension Fund

27 Sep 2013 12:14

Venn Life Sciences' 1st Half Loss Widens As It Ups Investment Spend

26 Apr 2013 15:11

Venn Life Sciences wins new contracts

Venn Life Sciences has won two contracts to provide a number of clinical trial-management services across Europe. The first contract is with a global pharmaceutical company to conduct a Phase IV drug interaction study and the second is with a leading US biotech company to manage a multi-national st

7 Feb 2013 11:12

Venn Life Sciences sets up Russian arm

Clinical research company Venn Life Sciences on Thursday said it expanded its operations with a new Russian business. The group has established Venn Russia, a joint venture with a local contract research organisation (CRO). The new arm will operate from offices in Moscow and will complement exist

Latest Share Chat

Venn Life Sciences Share News (VENN)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Rightmove Chairman sells 7m pounds of shares

Login to your account

Quickpicks are a member only feature

Login to your account